Test Price
2,800 AED✅ Home Collection Available
GABRA1 Genetic Susceptibility Testing for Childhood Absence Epilepsy Type 4 (NGS) in UAE
Executive Summary & Core Metrics
Core Metrics at a Glance
- Test Price: 2,800 AED
- Accuracy: 99.9% diagnostic sensitivity (ISO 9001:2015 accredited NGS)
- Turnaround Time: 3–4 weeks (ISO-controlled workflow)
- Sample Type: Peripheral blood (VIP mobile phlebotomy available daily 8 AM–11 PM)
- Clinical Support: Post-test telephonic interpretation by certified genetic counsellors
- Insurance: Direct billing verification via WhatsApp at +971 54 548 8731
Test Overview & Methodology
The GABRA1 NGS test evaluates the entire coding sequence of the GABRA1 gene to identify pathogenic variants linked to childhood absence epilepsy type 4 (CAE4). This high‑precision assay guides early diagnosis, personalised management, and family risk assessment. Methodology utilises Illumina® next‑generation sequencing with Sanger confirmation for all clinically significant variants.
| Feature | Our GABRA1 NGS Test (UAE Reference Lab) | Closest Alternative (Standard Exome) |
|---|---|---|
| Precision | 99.9% analytical sensitivity, full gene coverage | ~95% sensitivity, possible gaps in high‑GC regions |
| Methodology | Illumina NGS with Sanger confirmation | Exome capture, may miss intronic regulatory variants |
| Turnaround Time | 3–4 Weeks (ISO‑controlled workflow) | 6–10 Weeks (variable) |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403):
“A GABRA1 positive result clarifies the genetic basis of childhood absence epilepsy, but it must be interpreted alongside EEG findings and clinical history. A confirmed variant does not alter standard anti‑epileptic management without direct physician supervision. We always recommend post‑test genetic counselling to address family recurrence risks and reproductive options.”
Advisory: Medication Safety
⚠ Important Medication Warning
Do not discontinue prescribed anti‑epileptic medication without consulting your doctor. Abrupt cessation can trigger seizure recurrence or status epilepticus. All medication adjustments must be made under direct clinical supervision.
Exclusion Criteria
Contraindications for Testing
- Active severe infection or haemodynamic instability that contraindicates phlebotomy
- Known bleeding disorder without physician clearance
- Inability to provide informed consent/assent (guardian for minors)
- Emergencies such as prolonged tonic‑clonic seizure (>5 minutes), altered consciousness, or signs of anaphylaxis – seek immediate emergency care
Patient FAQ & Clinical Guidance
1. What is the GABRA1 susceptibility test for childhood absence epilepsy?
The GABRA1 NGS test detects disease‑causing variants in the GABRA1 gene that increase susceptibility to childhood absence epilepsy type 4 with 99.9% sensitivity. It is a definitive molecular diagnosis for children with typical absence seizures and a family history of epilepsy.
2. How is the sample collected for this test in the UAE?
A certified phlebotomist visits your home between 8 AM and 11 PM to draw a small blood sample using VIP mobile phlebotomy. The specimen is immediately placed in temperature‑controlled ISO‑certified cold‑chain containers and couriered to our Dubai Healthcare City laboratory for processing.
3. Will my health insurance cover the GABRA1 genetic test?
Direct billing verification via WhatsApp confirms coverage with major UAE insurers. A pre‑authorisation code is provided within one hour for eligible plans. Contact us at +971 54 548 8731 for a real‑time benefit check.
UAE Regulatory & Data Privacy Adherence
Data Protection & Legal Compliance
All genetic data is processed in strict adherence to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic information is encrypted, access‑controlled, and never shared without explicit consent.
Clinical & Logistical Metadata
| Test Name | GABRA1 Genetic Susceptibility Testing for Childhood Absence Epilepsy Type 4 (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Blood |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | G40.A0 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians